Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Dermatologic 5Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Sarcoma 727Glioblastoma 354Gliosarcoma 341Brain Neoplasms 254Central Nervous System Neoplasms 223Astrocytoma 204Osteosarcoma 202Gastrointestinal Stromal Tumors 176Dendritic Cell Sarcoma, Interdigitating 174Glioma 165Lymphoma 163Burkitt Lymphoma 162Precursor Cell Lymphoblastic Leukemia-Lymphoma 158Neoplasms 155Lymphoma, Non-Hodgkin 151Oligodendroglioma 147Recurrence 138Lymphoma, Large B-Cell, Diffuse 133Neuroblastoma 130Lymphoma, Follicular 127Breast Neoplasms 121Leukemia, Lymphocytic, Chronic, B-Cell 120Lymphoma, Mantle-Cell 119Leukemia 116Lymphoma, B-Cell, Marginal Zone 113Lymphoma, Large-Cell, Immunoblastic 112Rhabdomyosarcoma 111Hodgkin Disease 110Bone Neoplasms 109Sarcoma, Kaposi 102

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Sarcoma × Clear all
NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡